#shorts #news #trending #trendingshorts #breakingnews #desantis #news
Pfizer has been granted approval by the FDA to market Abrysvo, a vaccine designed to protect older adults from respiratory syncytial virus (RSV). This is the second RSV shot to be authorised in the US, following approval for a rival GlaxoSmithKline (GSK) shot earlier this month. The Centers for Disease Control and Prevention still need to sign off on any shot or treatment before it can reach the public. The agency’s independent advisory panel is expected to meet twice next month to make recommendations for both Pfizer and GSK for further discussion.
